Chemotherapeutic Treatment of Priapism in Metastatic Rectal Cancer

Y. Kitai    H. Takahashi    A. Goto    H. Iida    H. Mawatari
K. Fujita    M. Yoneda    M. Inamori    Y. Abe    N. Kobayashi
H. Kirikoshi    K. Kubota    S. Saito    A. Nakajima

Gastroenterology Division, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Key Words
Priapism · Metastatic rectal cancer · Chemotherapy

Abstract
A 65-year-old man was admitted with penile tenderness and dysuria due to priapism. Enhanced computed tomography revealed metastatic tumors in the liver, lung, sacrum and lymph nodes. Advanced rectal cancer, detected by colonoscopy as a primary tumor, was treated with chemotherapy (FOLFOX4). Although the rectal cancer showed no change, five months of chemotherapy improved the priapism, suggesting that chemotherapy can improve rare symptoms of rectal cancer.

Introduction
Although priapism has been reported as a complication of malignant tumor metastasis, leukemia, sickle cell disease, embolism and spinal canal stenosis [1–5], there are few reports of priapism as a complication of colorectal cancer in the absence of penile metastasis. Here we report a patient with rectal cancer with no penile metastasis in whom chemotherapy resulted in an improvement of priapism.

Case Report
A 65-year-old man was admitted to our hospital for priapism with tenderness of the penis and dysuria. Enhanced abdominal computed tomography demonstrated metastatic tumors in the liver, lung, sacrum (fig. 1a) and mediastinal or endopelvic lymph nodes, but no penile metastasis. Ultrasonography of the penis revealed no tumor and normal blood flow in the penis vessel. Advanced rectal cancer was detected by colonoscopy (fig. 2a). Chemotherapy (FOLFOX4; levofolinate 25 mg, fluorouracil 250 mg, oxaliplatin 100 mg) was administered, and although the primary rectal cancer showed no change...
(fig. 2b), sacral metastasis showed slight improvement (fig. 1b), and dysuria and priapism showed obvious improvement after 5 months.

Discussion

Brain or splenic metastasis and hypercalcemia arising from bone metastasis have been reported as rare complications of colorectal cancer \[6–8\]. Chemotherapy regimens for metastatic colorectal cancer include fluorouracil, leucovorin, either oxaliplatin or irinotecan, and the VEGF inhibitor bevacizumab \[9\]. Priapism is a complex involuntary behavioral response that depends on the integration of vascular, endocrine and neurological mechanisms. Stimuli for erection can be classified as psychogenic and reflexogenic \[10\]. When visceral nerves at the sacrum are stimulated electrically, this results in persistent penile erection. These efferent sacral nerves (S2–S4) are termed ‘nervi erigentes’. A second, thoracolumbar erection centre at the level of T12–L1 plays a role in psychogenically mediated erections via sympathetic efferent fibers. Disturbances in penile blood flow due to metastasis in the penis have been reported to cause priapism \[11\]. In this case, the cause of priapism might have been micrometastasis in the penis, metastatic tumors that affected the spinal cord, or continuous stimulation of nervi erigentes by a metastatic tumor. Chemotherapy, which reduced the metastatic tumor in the sacrum, may also have reduced the level of nervi erigentes stimulation. The results from this case suggest that chemotherapy can be effective for treating rare complications of rectal cancer such as priapism.

Fig. 1. Abdominal computed tomography showing metastatic tumor in sacrum before (a) and after chemotherapy (b).
Fig. 2. Colonoscopy showing type 2 tumor in the rectum before (a) and after chemotherapy (b).
References


